Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.
Lisa M. Barroilhet, MD
Advertisement
Articles by Lisa M. Barroilhet, MD
PARP inhibitors are the most commonly used targeted therapy for patients with recurrent ovarian cancer, and the indications for the use of these drugs have broadened in recent months.
Advertisement
Latest Updated Articles
PARP Inhibitors Are Changing Diagnostic and Therapeutic Landscape in Ovarian CancerPublished: August 16th 2017 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5